BlackRock
ACOR

BlackRock’s Acorda Therapeutics ACOR Stock Holding History

BlackRock’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,107
Closed -$80.7K – 5447
2024
Q1 		$80.7K Sell
6,107
-521
-8% -$7.56K ﹤0.01% 4782
2023
Q4 		$100K Sell
6,628
-150
-2% -$1.7K ﹤0.01% 4805
2023
Q3 		$102K Buy
6,778
+2
+0% +$30 ﹤0.01% 4842
2023
Q2 		$88.2K Buy
6,776
+3
+0% +$36 ﹤0.01% 4956
2023
Q1 		$79.4K Sell
6,773
-7
-0.1% -$116 ﹤0.01% 5016
2022
Q4 		$104K Sell
6,780
-9
-0.1% -$105 ﹤0.01% 5030
2022
Q3 		$40K Sell
6,789
-187
-3% -$1.56K ﹤0.01% 5401
2022
Q2 		$66K Sell
6,976
-1,298
-16% -$23.1K ﹤0.01% 5358
2022
Q1 		$266K Sell
8,274
-60
-0.7% -$2.36K ﹤0.01% 5040
2021
Q4 		$399K Buy
8,334
+237
+3% +$16.3K ﹤0.01% 4936
2021
Q3 		$744K Sell
8,097
-265
-3% -$22K ﹤0.01% 4647
2021
Q2 		$798K Sell
8,362
-1,149
-12% -$100K ﹤0.01% 4576
2021
Q1 		$927K Buy
9,511
+400
+4% +$49.1K ﹤0.01% 4516
2020
Q4 		$756K Buy
9,111
+59
+0.7% +$5.42K ﹤0.01% 4277
2020
Q3 		$559K Sell
9,052
-492
-5% -$37.1K ﹤0.01% 4246
2020
Q2 		$840K Sell
9,544
-51,472
-84% -$5.44M ﹤0.01% 4086
2020
Q1 		$6.83M Sell
61,016
-4,310
-7% -$848K ﹤0.01% 3195
2019
Q4 		$16M Buy
65,326
+37
+0.1% +$9.34K ﹤0.01% 3008
2019
Q3 		$22.5M Buy
65,289
+6,899
+12% +$3.75M ﹤0.01% 2748
2019
Q2 		$53.7M Buy
58,390
+2,349
+4% +$2.89M ﹤0.01% 2279
2019
Q1 		$89.4M Buy
56,041
+442
+0.8% +$796K ﹤0.01% 1939
2018
Q4 		$104M Buy
55,599
+6,926
+14% +$15.1M 0.01% 1775
2018
Q3 		$115M Sell
48,673
-8,538
-15% -$26.4M 0.01% 1886
2018
Q2 		$197M Buy
57,211
+3,366
+6% +$10.3M 0.01% 1472
2018
Q1 		$153M Buy
53,845
+14
+0% +$41.9K 0.01% 1555
2017
Q4 		$139M Buy
53,831
+1,501
+3% +$4.27M 0.01% 1637
2017
Q3 		$149M Sell
52,330
-1,148
-2% -$3.02M 0.01% 1575
2017
Q2 		$126M Sell
53,478
-66
-0.1% -$131K 0.01% 1640
2017
Q1 		$135M Buy
53,544
+53,459
+62,893% +$154M 0.01% 1571
2016
Q4 		$194K Sell
85
-63
-43% -$150K ﹤0.01% 2161
2016
Q3 		$370K Buy
148
+39
+36% +$116K ﹤0.01% 1861
2016
Q2 		$333K Buy
109
+84
+336% +$273K ﹤0.01% 1843
2016
Q1 		$78K Buy
25
+14
+127% +$58.1K ﹤0.01% 2120
2015
Q4 		$57K Buy
11
+2
+22% +$8.74K ﹤0.01% 1983
2015
Q3 		$29K Sell
9
-28
-76% -$109K ﹤0.01% 2177
2015
Q2 		$149K Sell
37
-51
-58% -$197K ﹤0.01% 1730
2015
Q1 		$352K Buy
88
+69
+363% +$316K ﹤0.01% 1587
2014
Q4 		$93K Hold
19
– – ﹤0.01% 1754
2014
Q3 		$77K Buy
19
+9
+90% +$33.8K ﹤0.01% 1780
2014
Q2 		$39K Sell
10
-674
-99% -$2.75M ﹤0.01% 2048
2014
Q1 		$3.11M Buy
684
+47
+7% +$190K 0.01% 944
2013
Q4 		$2.23M Buy
637
+450
+241% +$1.75M ﹤0.01% 1007
2013
Q3 		$769K Buy
187
+7
+4% +$30.2K ﹤0.01% 1144
2013
Q2 		$714K Buy
+180
New +$741K ﹤0.01% 1136

Other funds holding ACOR

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock's ACOR Position: Q2 2024 in Review

BlackRock sold out of Acorda Therapeutics (ACOR) in Q2 2024, closing a stake of 6,107 shares — an estimated $80.7K sold.

BlackRock first reported a position in ACOR in Q2 2013 and held it in 44 quarters. The position peaked at $197M in Q2 2018. 2 funds tracked by Wall St. Rank hold ACOR as of Q2 2024.

  • BlackRock reported no remaining Acorda Therapeutics position as of Q2 2024 after selling out during the quarter.
  • BlackRock sold 6,107 Acorda Therapeutics shares in Q2 2024, an estimated $80.7K.
  • BlackRock first reported a position in Acorda Therapeutics in Q2 2013 and held it in 44 quarters.
  • BlackRock's Acorda Therapeutics position peaked at $197M in Q2 2018.
  • 2 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2024.

Based on BlackRock's 13F filing for Q2 2024, filed 13 Aug 2024.